- Our Focus
Leading with the heart
Cardiovascular diseases are the No. 1 cause of death globally, according to the World Health Organization. At Novartis, we focus on developing new treatment options for people living with serious cardio-metabolic diseases.
Heart failure is a debilitating and potentially life-threatening condition where the heart cannot pump enough blood around the body, leaving patients fatigued, short of breath, and at risk of sudden cardiac death. This, in most cases, happens because the heart muscle responsible for the pumping action weakens or stiffens over time.
How much do you know about heart failure? Take the quiz
Living with heart failure: one person’s perspective
Join the community. Follow us on Twitter.
Atherosclerosis and Heart Attack
Atherosclerosis is the buildup of cholesterol and inflammatory cells in the artery walls that can restrict blood flow and cause blood clots. It is the most common underlying cause of a heart attack, which occurs when a blood clot stops blood flow and oxygen supply to a part of the heart, causing damage to the heart muscle.
What is inflammatory atherosclerosis?
It is estimated that in people who have had a heart attack, the risk of having another heart attack or stroke is related to increased inflammation of the blood vessels. This characteristic has been described as inflammatory atherosclerosis. At Novartis, we are actively participating in research and clinical development in this highly innovative and novel field of cardiovascular medicine.
Our motto – "leading with the heart" – defines our culture and our commitment to tackling large-scale public health issues. Join us.
- Medical Representative Cardio Metabolic
Petach Tikva, Israel
- Account Specialist - Respiratory
- Brand Manager Cardio-Metabolic (FTC)
- WorldWide Associate Brand Director - Cardio Metabolic